225 related articles for article (PubMed ID: 21879446)
1. The biology and therapeutic implications of HDACs in the heart.
McKinsey TA
Handb Exp Pharmacol; 2011; 206():57-78. PubMed ID: 21879446
[TBL] [Abstract][Full Text] [Related]
2. Targeting histone deacetylases for heart failure.
Bush EW; McKinsey TA
Expert Opin Ther Targets; 2009 Jul; 13(7):767-84. PubMed ID: 19466913
[TBL] [Abstract][Full Text] [Related]
3. Isoform-selective HDAC inhibitors: closing in on translational medicine for the heart.
McKinsey TA
J Mol Cell Cardiol; 2011 Oct; 51(4):491-6. PubMed ID: 21108947
[TBL] [Abstract][Full Text] [Related]
4. Protein acetylation in the cardiorenal axis: the promise of histone deacetylase inhibitors.
Bush EW; McKinsey TA
Circ Res; 2010 Feb; 106(2):272-84. PubMed ID: 20133912
[TBL] [Abstract][Full Text] [Related]
5. Therapeutic potential for HDAC inhibitors in the heart.
McKinsey TA
Annu Rev Pharmacol Toxicol; 2012; 52():303-19. PubMed ID: 21942627
[TBL] [Abstract][Full Text] [Related]
6. Control of cardiac hypertrophy and heart failure by histone acetylation/deacetylation.
Olson EN; Backs J; McKinsey TA
Novartis Found Symp; 2006; 274():3-12; discussion 13-9, 152-5, 272-6. PubMed ID: 17019803
[TBL] [Abstract][Full Text] [Related]
7. Therapeutic effects of histone deacetylase inhibitors on heart disease.
Chun P
Arch Pharm Res; 2020 Dec; 43(12):1276-1296. PubMed ID: 33245518
[TBL] [Abstract][Full Text] [Related]
8. HDAC-dependent ventricular remodeling.
Xie M; Hill JA
Trends Cardiovasc Med; 2013 Aug; 23(6):229-35. PubMed ID: 23499301
[TBL] [Abstract][Full Text] [Related]
9. Heart failure: the pivotal role of histone deacetylases.
Hewitson R; Dargan J; Collis D; Green A; Moorjani N; Ohri S; Townsend PA
Int J Biochem Cell Biol; 2013 Feb; 45(2):448-53. PubMed ID: 23178536
[TBL] [Abstract][Full Text] [Related]
10. Non-sirtuin histone deacetylases in the control of cardiac aging.
Ferguson BS; McKinsey TA
J Mol Cell Cardiol; 2015 Jun; 83():14-20. PubMed ID: 25791169
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of class I histone deacetylase with an apicidin derivative prevents cardiac hypertrophy and failure.
Gallo P; Latronico MV; Gallo P; Grimaldi S; Borgia F; Todaro M; Jones P; Gallinari P; De Francesco R; Ciliberto G; Steinkühler C; Esposito G; Condorelli G
Cardiovasc Res; 2008 Dec; 80(3):416-24. PubMed ID: 18697792
[TBL] [Abstract][Full Text] [Related]
12. Derepression of pathological cardiac genes by members of the CaM kinase superfamily.
McKinsey TA
Cardiovasc Res; 2007 Mar; 73(4):667-77. PubMed ID: 17217938
[TBL] [Abstract][Full Text] [Related]
13. Histone deacetylases as regulators of inflammation and immunity.
Shakespear MR; Halili MA; Irvine KM; Fairlie DP; Sweet MJ
Trends Immunol; 2011 Jul; 32(7):335-43. PubMed ID: 21570914
[TBL] [Abstract][Full Text] [Related]
14. Lysine acetyltransferases and lysine deacetylases as targets for cardiovascular disease.
Li P; Ge J; Li H
Nat Rev Cardiol; 2020 Feb; 17(2):96-115. PubMed ID: 31350538
[TBL] [Abstract][Full Text] [Related]
15. Targeting inflammation in heart failure with histone deacetylase inhibitors.
McKinsey TA
Mol Med; 2011; 17(5-6):434-41. PubMed ID: 21267510
[TBL] [Abstract][Full Text] [Related]
16. Posttranslational modifications of histone deacetylases: implications for cardiovascular diseases.
Eom GH; Kook H
Pharmacol Ther; 2014 Aug; 143(2):168-80. PubMed ID: 24594235
[TBL] [Abstract][Full Text] [Related]
17. The Crosstalk between Acetylation and Phosphorylation: Emerging New Roles for HDAC Inhibitors in the Heart.
Habibian J; Ferguson BS
Int J Mol Sci; 2018 Dec; 20(1):. PubMed ID: 30597863
[TBL] [Abstract][Full Text] [Related]
18. Histone deacetylases--an important class of cellular regulators with a variety of functions.
Hildmann C; Riester D; Schwienhorst A
Appl Microbiol Biotechnol; 2007 Jun; 75(3):487-97. PubMed ID: 17377789
[TBL] [Abstract][Full Text] [Related]
19. Protein deacetylases: enzymes with functional diversity as novel therapeutic targets.
Yoshida M; Shimazu T; Matsuyama A
Prog Cell Cycle Res; 2003; 5():269-78. PubMed ID: 14593721
[TBL] [Abstract][Full Text] [Related]
20. Toward transcriptional therapies for the failing heart: chemical screens to modulate genes.
McKinsey TA; Olson EN
J Clin Invest; 2005 Mar; 115(3):538-46. PubMed ID: 15765135
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
